New STAMPEDE data support earlier CHAARTED trial results

So here’s the first important finding that will be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. Data from the UK’s STAMPEDE trial show a significant benefit from combining docetaxel-based chemotherapy with androgen deprivation therapy (ADT) in appropriately selected men. … READ MORE …

Statin therapy appears to extend progression-free survival for men on ADT

A combination of two studies by a group of researchers at the Dana-Farber Cancer Institute in Boston has provided some further evidence of the potential benefits of statin therapy for men being treated with androgen deprivation therapy (ADT) … but the evidence is preliminary and needs validation. … READ MORE …

Extending life in late-stage prostate cancer, but extending quality of life too

An article in the April issue of Lancet Oncology has provided additional data from the randomized, double-blind Phase III PREVAIL trial of enzalutamide versus placebo in men with asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

Long-term survival of hormone-naive patients in biochemical failure post-surgery

A new paper in the European Journal of Nuclear Medicine and Molecular Imaging provides some interesting data on the long-term survival of men with progressive prostate cancer after initial treatment by radical prostatectomy. … READ MORE …

Survival times among men with biochemically recurrent prostate cancer

It would hardly come as a shock to most experienced prostate cancer advocates and patients to learn that there is an association between survival time and the aggressiveness of a patient’s cancer at the time of diagnosis if that cancer progresses. … READ MORE …

The EMBARK trial in men with progressive but non-metastatic prostate cancer

We apparently managed to miss providing readers with information about initiation of what may be a game-changing, randomized, Phase III, trial in the treatment of progressive prostate cancer. … READ MORE …

Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,342 other followers